163 related articles for article (PubMed ID: 31285885)
1. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer.
Koyama J; Horiike A; Yoshizawa T; Dotsu Y; Ariyasu R; Saiki M; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ninomiya H; Ishikawa Y; Nishio M
J Thorac Dis; 2019 May; 11(5):1919-1928. PubMed ID: 31285885
[TBL] [Abstract][Full Text] [Related]
2. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
Ibusuki R; Yoneshima Y; Hashisako M; Matsuo N; Harada T; Tsuchiya-Kawano Y; Kishimoto J; Ota K; Shiraishi Y; Iwama E; Tanaka K; Oda Y; Okamoto I
Transl Lung Cancer Res; 2022 Nov; 11(11):2208-2215. PubMed ID: 36519019
[TBL] [Abstract][Full Text] [Related]
3. Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.
Chilelli MG; Signorelli C; Giron Berrios JR; Onorato A; Nelli F; Fabbri MA; Primi F; Marrucci E; Virtuoso A; Schirripa M; Mazzotta M; Ruggeri EM
Cancer Diagn Progn; 2022; 2(1):55-63. PubMed ID: 35400002
[TBL] [Abstract][Full Text] [Related]
4. Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer.
Iso H; Hisakane K; Mikami E; Suzuki T; Matsuki S; Atsumi K; Nagata K; Seike M; Hirose T
Transl Lung Cancer Res; 2023 Sep; 12(9):1850-1861. PubMed ID: 37854151
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival.
Haque AK; Syed S; Lele SM; Freeman DH; Adegboyega PA
Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):103-9. PubMed ID: 12051626
[TBL] [Abstract][Full Text] [Related]
6. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
7. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung.
Pelosi G; Fraggetta F; Pasini F; Maisonneuve P; Sonzogni A; Iannucci A; Terzi A; Bresaola E; Valduga F; Lupo C; Viale G
Am J Surg Pathol; 2001 Mar; 25(3):363-72. PubMed ID: 11224607
[TBL] [Abstract][Full Text] [Related]
8. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins.
Myong NH
J Korean Med Sci; 2003 Aug; 18(4):494-500. PubMed ID: 12923324
[TBL] [Abstract][Full Text] [Related]
9. Immune-related thyroid dysfunction in patients with non-small cell lung cancer.
Cai C; Zhou S; Qu J; Zhou J
J Thorac Dis; 2024 Jan; 16(1):253-263. PubMed ID: 38410546
[TBL] [Abstract][Full Text] [Related]
10. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.
Tan D; Li Q; Deeb G; Ramnath N; Slocum HK; Brooks J; Cheney R; Wiseman S; Anderson T; Loewen G
Hum Pathol; 2003 Jun; 34(6):597-604. PubMed ID: 12827614
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
Furuya N; Nishino M; Wakuda K; Ikeda S; Sato T; Ushio R; Tanzawa S; Sata M; Ito K
Thorac Cancer; 2021 Mar; 12(5):613-618. PubMed ID: 33448648
[TBL] [Abstract][Full Text] [Related]
12. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials.
Huang J; Zhang Y; Sheng J; Zhang H; Fang W; Zhan J; Zhou T; Chen Y; Liu L; Zhang L
Onco Targets Ther; 2016; 9():5867-5874. PubMed ID: 27713640
[TBL] [Abstract][Full Text] [Related]
14. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
15. Predictive significance of thyroid transcription factor-1 expression in patients with non-squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib.
Nakahara Y; Hosomi Y; Saito M; Ogawa M; Hishima T; Okamura T; Sasaki J; Masuda N
Mol Clin Oncol; 2016 Jul; 5(1):14-18. PubMed ID: 27330756
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
[TBL] [Abstract][Full Text] [Related]
17. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
Duruisseaux M; Martínez-Cardús A; Calleja-Cervantes ME; Moran S; Castro de Moura M; Davalos V; Piñeyro D; Sanchez-Cespedes M; Girard N; Brevet M; Giroux-Leprieur E; Dumenil C; Pradotto M; Bironzo P; Capelletto E; Novello S; Cortot A; Copin MC; Karachaliou N; Gonzalez-Cao M; Peralta S; Montuenga LM; Gil-Bazo I; Baraibar I; Lozano MD; Varela M; Ruffinelli JC; Palmero R; Nadal E; Moran T; Perez L; Ramos I; Xiao Q; Fernandez AF; Fraga MF; Gut M; Gut I; Teixidó C; Vilariño N; Prat A; Reguart N; Benito A; Garrido P; Barragan I; Emile JF; Rosell R; Brambilla E; Esteller M
Lancet Respir Med; 2018 Oct; 6(10):771-781. PubMed ID: 30100403
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
20. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
